Multiple system atrophy

Relief of disease progression by CS10BR05

Multiple system atrophy - 코아스템(주)
  • Development stage: Completion of non-clinical, application for approval of first-phase clinical trial
  • Mechanisms of action: Suppressing neuronal cell death and alpha-synuclein through neuroprotective factor expression
  • Injection route: Carotid injection

Multiple system atrophy is a neurodegenerative disease of the central nervous system which is accompanied by signs of autonomic imbalance (orthostatic hypotension, urinary problems, erectile dysfunction), Parkinson's symptoms (movement decreases, limb tremors) and cerebellar ataxia symptoms (grogginess, pronounced incorrectly). It shows signs similar to Parkinson's disease, however, it doesn’t show improvement of symptoms by dopaminergic drugs and occurs at any age.

Multiple system atrophy is primarily caused by abnormal deposition of alpha-synuclein proteins in the central nervous system such as basal ganglia, cerebellum ad spinal cord including the substantia nigra . The nerve cell death caused by brain inflammation is appeared secondarily.

Through the non-clinical trial, it was confirmed that CS10BR05 secretes neuroprotective factors and cytokines, improves the ability to act on disease model of multiple system atrophy and reduces the loss of nerve cells. It also was confirmed that Carotid injection shows higher cell reach rate to site of lesion, compared to intravenous injection.

We have completed the non-clinical trial and are applying first-phase clinical trial.


Autologous Mesenchymal Stem Cell Therapy Delays the Progression of Neurological Deficits in Patients With Multiple System Atrophy. CLINICAL PHARMACOLOGY & THERAPEUTICS 2008;83:723-730

Bone Marrow-Derived Mesenchymal Stem Cell Therapy as a Candidate Disease-Modifying Strategy in Parkinson’s Disease and Multiple System Atrophy. J Clin Neurol 2009;5:1-10

Neuroprotective Effect of Human Mesenchymal Stem Cells in an Animal Model of Double Toxin-Induced Multiple System Atrophy Parkinsonism. Cell Transplantation 2011;20:827-835

Randomized Trial of Mesenchymal Stem Cells in Multiple System Atrophy. ANN NEUROL 2012;72:32-40